Multiple Sclerosis Spotlight: Relapsing-Remitting
Multiple sclerosis (MS) is a disease that affects the brain and central nervous system. Symptoms and severity vary depending on the type and amount of damage that occurs. The most common type is relapsing-remitting multiple sclerosis (RRMS), affecting about 85% of those diagnosed.
MS Types
Our nerve fibers help the brain communicate with the rest of the body. They have a protective cover called myelin on them. In MS, the immune system mistakenly attacks the myelin, eventually causing deterioration or permanent nerve damage. Thus, resulting in movement problems, vision disturbances, and other issues. The damage could be in one area or multiple. Damage to nerves can still occur even though there are no symptoms. No two people will have the same experiences. Symptoms experienced:
- Tremor, lack of coordination, or unsteady gait
- Partial or complete loss of vision and pain with eye movement
- Prolonged double vision
- Blurry vision
- Slurred speech
- Fatigue
- Dizziness
- Tingling or pain in parts of your body
Multiple sclerosis types are characterized by disease progression, frequency of relapses (exacerbations), presenting symptoms, and period of remission. The most common are:
- Relapsing-Remitting (RRMS): Clearly defined relapse of symptoms, followed periods where all symptoms go into remission, or just a few. Also, the progression of the disease isn’t typical during remission.
- Secondary-Progressive (SPMS): This type has a steady worsening of neurological function that continues with or without a relapse of symptoms. Some with RRMS will eventually transition to this stage.
- Primary-Progressive (PPMS): PPMS is characterized by gradual worsening symptoms from the beginning, without relapses or remissions.
Relapsing-remitting multiple sclerosis involves many more attacks than the other more progressive types. Brain and inflammatory lesions are also more familiar with RRMS, though disease progression stops during remission.
Modifying the Course of RRMS
Treating RRMS mainly involves using disease-modifying therapies (DMT). Over a dozen are FDA approved to treat MS, and they help reduce the number of attacks and help slow disease progression. DMT’s also decrease the number of brain and spinal cord lesions. As researchers continue to learn about other ways to reduce new lesions and relapses, the course of RRMS is altered.
New RRMS therapies under investigation include medical marijuana, stem cell therapy, lipoic acid, and more. As a clinical research volunteer, you can help change the future for those with multiple sclerosis. ActivMed currently needs participants to join enrolling studies at our Lawrence, MA location for those with relapsing-remitting or secondary-progressive multiple sclerosis. View additional information on our website, or call (978) 992-4239.
References:
https://www.nationalmssociety.org/What-is-MS/Types-of-MS/Relapsing-remitting-MS#section-3
https://www.mayoclinic.org/diseases-conditions/multiple-sclerosis/diagnosis-treatment/drc-20350274
- Blog (139)
- Alzheimer's Disease (18)
- Atopic Dermatitis (4)
- Alzheimers Clinical Trials (2)
- Charity Event (2)
- Chronic Conditions (2)
- #CTD2020 (1)
- 2019 (1)
- Acne (1)
- Adolescent (1)
- Advice (1)
- Age Friendly (1)
- Alzheimer's Agitation (1)
- Alzheimer's Research (1)
- Alzheimer's and Brain Awareness Month (1)
- Alzheimers Study (1)
- American Heart Association (1)
- American Heart Month (1)
- American Stroke Month (1)
- Annual (1)
- Article (1)
- Atopic Dermatitis Care (1)
- Baseline Memory Screen (1)
- Binge Eating (1)
- Blood Pressure (1)
- Brain Health (1)
- Caregiver (1)
- Chronic Pain (1)
- April 2022 (2)
- March 2022 (2)
- February 2022 (2)
- January 2022 (2)
- December 2021 (2)
- November 2021 (2)
- October 2021 (2)
- September 2021 (2)
- August 2021 (3)
- July 2021 (2)
- June 2021 (1)
- May 2021 (1)
- April 2021 (2)
- March 2021 (2)
- February 2021 (3)
- January 2021 (2)
- December 2020 (2)
- November 2020 (3)
- October 2020 (2)
- September 2020 (3)
- August 2020 (4)
- July 2020 (3)
- June 2020 (3)
- May 2020 (5)
- April 2020 (2)
- March 2020 (6)
- February 2020 (2)
- January 2020 (4)
- December 2019 (3)
- November 2019 (5)
- October 2019 (8)
- September 2019 (3)
- August 2019 (3)
- July 2019 (3)
- June 2019 (5)
- May 2019 (6)
- April 2019 (5)
- March 2019 (3)
- February 2019 (2)
- January 2019 (2)
- December 2018 (4)
- November 2018 (3)
- October 2018 (5)
- September 2018 (5)
- August 2018 (8)
- July 2018 (6)
- June 2018 (5)
- May 2018 (4)
- April 2018 (6)
- March 2018 (4)
- February 2018 (1)
- January 2018 (2)
- December 2017 (2)
- November 2017 (4)
- October 2017 (1)
- September 2017 (1)
- August 2017 (2)
- July 2017 (1)
- May 2017 (2)
- April 2017 (2)
- March 2017 (4)
- September 2016 (2)
- August 2016 (3)
- July 2016 (1)
- May 2016 (2)
- April 2016 (1)
- March 2016 (1)
- February 2016 (1)
- January 2016 (3)
- October 2014 (1)
